Cyrano Therapeutics完成CYR-064治疗病毒后嗅觉丧失的二期FLAVOR试验受试者招募-动脉网

Cyrano Therapeutics Completes Enrollment in Phase 2 FLAVOR Trial of CYR-064 for Post-Viral Smell Loss

CISION 等信源发布 2025-04-10 20:33



可切换为仅中文







Data Expected in Q4 2025 from Study Evaluating the First Potential Therapy for Post-Viral Hyposmia

预计2025年第四季度将公布评估首个潜在治疗后病毒性嗅觉减退疗法的研究数据

DELRAY BEACH, Fla.

佛罗里达州德尔雷海滩

，

April 10, 2025

2025年4月10日

/PRNewswire/ -- Cyrano Therapeutics, Inc., a clinical-stage regenerative medicine company pioneering the development of treatments for smell loss, today announced that it has completed enrollment in the Phase 2 FLAVOR trial, a randomized, double-blinded, placebo-controlled, multi-dose clinical study evaluating CYR-064, its novel soft-mist nasal spray product candidate, for the treatment of post-viral hyposmia (smell loss). Data from the trial is expected in the fourth quarter of 2025..

/PRNewswire/ -- 致力于开发嗅觉丧失治疗方法的临床阶段再生医学公司Cyrano Therapeutics, Inc.今天宣布，已完成二期FLAVOR试验的入组。这是一项随机、双盲、安慰剂对照、多剂量临床研究，旨在评估其新型软雾鼻喷剂候选产品CYR-064治疗病毒后嗅觉减退（嗅觉丧失）的效果。该试验的数据预计将于2025年第四季度公布。

The FLAVOR trial enrolled 150 patients across 14 clinical sites in

FLAVOR试验在14个临床站点共招募了150名患者

the United States

美国

to assess the safety, tolerability, and efficacy of CYR-064 for the treatment for post-viral hyposmia compared to placebo over a six-month period. Post-viral hyposmia, a chronic sensory condition with no FDA-approved treatment, is an increasingly prevalent issue affecting more than 60 million people between the US, .

评估CYR-064治疗病毒后嗅觉减退的安全性、耐受性和疗效，与安慰剂对比，为期六个月。病毒后嗅觉减退是一种慢性感官疾病，目前尚无FDA批准的治疗方法，这一问题日益普遍，在美国等地影响超过6000万人。

Europe

欧洲

and

和

Japan

日本

, and millions more worldwide.

，全球范围内还有数百万人。

'Completion of enrollment in our FLAVOR trial is a significant milestone in our mission to develop the first potential pharmaceutical treatment for post-viral smell loss,' said

“我们在FLAVOR试验中的注册完成是我们开发首个潜在的治疗后病毒性嗅觉丧失的药物的重要里程碑，”表示。

Rick Geoffrion

里克·杰夫里翁

, President and CEO of Cyrano Therapeutics, Inc. 'We are deeply grateful to the patients and investigators who have contributed to this critical research, and we look forward to analyzing the data, which will be instrumental in guiding the next phase of CYR-064's development.'

Cyrano Therapeutics公司总裁兼首席执行官表示：“我们对参与这项关键研究的患者和研究人员深表感谢，并期待分析数据，这将对指导CYR-064的下一阶段开发起到至关重要的作用。”

CYR-064 is a patent-protected, intranasal formulation of a broad-spectrum phosphodiesterase (PDE) inhibitor designed to enhance olfactory neuron excitability and restore the sense of smell. A key component of CYR-064's delivery system is Ursatec's

CYR-064 是一种受专利保护的鼻腔给药广谱磷酸二酯酶（PDE）抑制剂，旨在增强嗅觉神经元的兴奋性并恢复嗅觉。CYR-064 递送系统的关键成分是 Ursatec 的技术。

pumpsystem in combination with the Resyca soft mist spray technology, which enables precise, targeted deposition of the drug into the olfactory region. By utilizing a soft-mist formulation with controlled droplet size and low spray velocity, the

泵系统与Resyca软雾喷雾技术相结合，能够将药物精确、有针对性地沉积到嗅觉区域。通过使用具有可控液滴大小和低喷射速度的软雾配方，

-Ultra Soft system enhances drug deposition and absorption and increases the potential for therapeutic efficacy. This advanced delivery mechanism is designed to optimize patient outcomes while ensuring ease of administration.

超柔软系统可增强药物沉积和吸收，并提高治疗效果的潜力。这种先进的递送机制旨在优化患者疗效，同时确保给药便捷性。

'Completing enrollment in the FLAVOR trial is an important milestone in our efforts to bring forward the first potential treatment for patients suffering from post-viral hyposmia,' said Mas Takashima, MD FACS, Professor and Chairman of the Department of Otolaryngology – Head and Neck Surgery at Houston Methodist Hospital and the principal investigator for the FLAVOR trial.

“完成FLAVOR试验的入组是我们为后病毒性嗅觉减退患者带来首个潜在治疗手段的重要里程碑，”休斯顿卫理公会医院耳鼻喉头颈外科教授兼主任、FLAVOR试验的首席研究员Mas Takashima医学博士表示。

'We are encouraged by the commitment of the patients who participated and are eager to review the results and validate the promise of CYR-064 which has the potential to provide the first evidence-based treatment for patients suffering from post-viral hyposmia..'.

“我们受到参与患者的承诺的鼓舞，并渴望审查结果，验证CYR-064的潜力，它有可能为遭受病毒感染后嗅觉减退的患者提供首个基于证据的治疗。”

About Cyrano Therapeutics

关于Cyrano Therapeutics

Cyrano Therapeutics is a private, venture-backed clinical stage regenerative medicine company. Since our foundation, we have been working diligently to develop therapies for people struggling with the loss of smell and taste. To learn more, please visit

Cyrano Therapeutics 是一家私人投资支持的临床阶段再生医学公司。自成立以来，我们一直致力于为那些失去嗅觉和味觉的人们开发治疗方法。欲了解更多信息，请访问

cyranotherapeutics.com

西瑞诺治疗学公司网站

。

Media Contact:

媒体联系人：

Tiberend Strategic Advisors, Inc.

Tiberend战略顾问公司

Eric Reiss

埃里克·里斯

ereiss@tiberend.com

SOURCE Cyrano Therapeutics